De novo design of inhibitors of DNA methyltransferase 1: A critical comparison of ligand- and structure-based approaches

25 April 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Designing and developing inhibitors against the epigenetic target DNA methyltransferase (DNMT) is an attractive strategy in epigenetic drug discovery. DNMT1 is one of the epigenetic enzymes with significant clinical relevance. Structure-based de novo design is a drug discovery strategy used in combination with similarity searching to identify a novel DNMT inhibitor with a novel chemical scaffold and warrants further exploration. This study aimed to continue exploring the potential of de novo design to build epigenetic-focused libraries targeted toward DNMT1. Herein, we report the results of an in-depth and critical comparison of ligand- and structure-based de novo design of screening libraries focused on DNMT1. The newly designed chemical libraries focused on DNMT1 are freely available on GitHub at https://github.com/DIFACQUIM/De-Novo_DNMT1.

Keywords

chemoinformatics
drug discovery
docking
epigenetics
Epigenetic Target Profiler
focused libraries
fragments
library design
open-access

Supplementary materials

Title
Description
Actions
Title
Supplementary Figure and Tables
Description
One supplementary figure and 14 supplementary tables.
Actions

Supplementary weblinks

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.